Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [published correction appears in Lancet 1999 Aug 14;354(9178):602]. Lancet. 1998;352(9131):837–853.

ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572. doi:https://doi.org/10.1056/NEJMoa0802987

Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published correction appears in N Engl J Med. 2007 Jul 5;357(1):100.]. N Engl J Med. 2007;356(24):2457–71. https://doi.org/10.1056/NEJMoa072761.

Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials [published correction appears in BMJ. 2022 Jan 18;376:o109]. BMJ. 2021;372:m4573. https://doi.org/10.1136/bmj.m4573(Published 2021 Jan 13).

Ala M. SGLT2 inhibition for cardiovascular diseases, chronic kidney disease, and NAFLD. Endocrinology. 2021;162(12):bqab157. https://doi.org/10.1210/endocr/bqab157.

Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653–62. https://doi.org/10.1016/S2213-8587(21)00203-5.

Article  CAS  PubMed  Google Scholar 

ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140–57. https://doi.org/10.2337/dc23-S009.

Sağlık Uygulama Tebliği. Part 4.2.38, diabetes medications use policy. Sosyal Güvenlik kurumu, SGK. https://www.sgk.gov.tr/Duyuru/Detay/20230316-Degisiklik-Tebligi-Islenmis-Guncel-2013-SUT-2023-03-20-02-54-56. Retrieved 21 Apr 2023.

Choi JG, Winn AN, Skandari MR, et al. First-line therapy for type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a cost-effectiveness study. Ann Intern Med. 2022;175(10):1392–400. https://doi.org/10.7326/M21-2941.

Article  PubMed  PubMed Central  Google Scholar 

Reifsnider OS, Kansal AR, Gandhi PK, et al. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease. BMJ Open Diabetes Res Care. 2021;9(1):e001313. https://doi.org/10.1136/bmjdrc-2020-001313.

Article  PubMed  PubMed Central  Google Scholar 

World Economic Outlook Database, April 2023. imf.org. International Monetary Fund. Retrieved 10 May 2023.